奈玛特韦上市后安全性信号:FAERS数据库的不比例分析
主要安全信号包括疾病复发(ROR=413.2)、味觉障碍(ROR=110.84)、嗅觉丧失(ROR=15.21)、味觉丧失(ROR=9.80)和荨麻疹(ROR=1.91),上腹痛和皮肤毒性为特异性信号。孕妇群体中危及生命状况的ROR显著升高(ROR=8.00)。
要点
- 疾病复发和味觉障碍是奈玛特韦最主要的安全信号,ROR分别为413.2和110.84。
- 上腹痛和皮肤毒性为奈玛特韦特异性安全信号,临床需关注。
- 孕妇中危及生命状况报告比值比显著升高(ROR=8.00),但事件数少需持续监测。
核心结论
- 奈玛特韦的主要安全信号为疾病复发、味觉障碍、上腹痛和皮肤毒性。
- 临床医生和药师应警惕这些不良事件,但区分COVID-19症状与不良事件具有挑战性。
- 孕妇群体中危及生命状况的潜在安全性 concern 需基于少量事件予以警告,数据尚不充分,需持续药物警戒和监测。
研究设计与样本
- 基于FDA不良事件报告系统(FAERS)2022年数据的药物警戒研究。
- 采用病例/非病例方法估计报告比值比(ROR)和信息成分(IC)及其95%置信区间。
主要发现
- 疾病复发ROR(95% CI)=413.2(395.6-431.59)。
- 味觉障碍ROR(95% CI)=110.84(106.04-115.85)。
- 嗅觉丧失ROR(95% CI)=15.21(12.76-18.11)。
- 味觉丧失ROR(95% CI)=9.80(8.50-11.3)。
- 荨麻疹ROR(95% CI)=1.91(1.69-2.17)。
关键数值与推荐
- 上腹痛和皮肤毒性被识别为奈玛特韦的特异性安全信号。
- 孕妇群体中危及生命状况的ROR(95% CI)=8.00(1.77-36.20)。
临床怎么用
- 临床药师应关注奈玛特韦治疗后的疾病复发、味觉障碍、上腹痛和皮肤毒性等不良事件。
- 对孕妇使用奈玛特韦需警惕潜在危及生命状况,尽管事件数少,应加强监测。
- 在区分COVID-19症状与药物不良事件时需谨慎评估。
局限性
- 基于自发报告数据,存在报告偏倚和混杂因素,无法确定因果关系。
- 孕妇群体安全性信号基于少量事件,数据不充分。
- 需要进一步持续的药物警戒和监测以充分理解奈玛特韦的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Nirmatrelvir is an antiviral drug with a novel mechanism of action, targeting the 3-CL protease, and is used in the treatment of COVID-19. However, the potential side effects have not yet been fully studied. The aim of this study was to identify potential safety signals of nirmatrelvir by analysing post-marketing safety data based on the largest publicly available worldwide pharmacovigilance database. METHODS: We analysed nirmatrelvir adverse events to identify and characterize relevant safety signals based on the FDA Adverse Event Reporting System database in 2022. The case/non-case approach was used to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for adverse events (AEs) that numbered 4 or more. RESULTS: A total of 26 846 cases were included. Disease recurrence (ROR [95% CI] = 413.2 [395.6-431.59]), dysgeusia (ROR [95% CI] = 110.84 [106.04-115.85]), anosmia (ROR [95% CI] = 15.21 [12.76-18.11]), ageusia (ROR [95% CI] = 9.80 [8.50-11.3]) and urticaria (ROR [95% CI] = 1.91 [1.69-2.17]) were the main safety signals. In addition, abdominal pain upper and skin toxicity were two specific safety signals of nirmatrelvir. In the pregnant population, there was a significant increased ROR for life-threatening conditions (ROR [95% CI] = 8.00 [1.77-36.20]). CONCLUSIONS: Our study identified that the main and specific safety signals of nirmatrelvir were disease recurrence, dysgeusia, abdominal pain upper and skin toxicity. Clinicians and pharmacists should be vigilant of these AEs, although differentiating between COVID-19 symptoms and AEs can be challenging. Notably, a potential safety concern of nirmatrelvir should be a warning based on a small number of events in the pregnant population. However, the available data are insufficient, and further continued pharmacovigilance and surveillance is needed to fully understand this issue.
引用
- Zhuang W, Xu J, Wu Y, et al. Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Br J Clin Pharmacol. 2023. PMID: 37170890. doi:10.1111/bcp.15783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。